JP7562558B2 - プラスミドシステム - Google Patents
プラスミドシステム Download PDFInfo
- Publication number
- JP7562558B2 JP7562558B2 JP2021560095A JP2021560095A JP7562558B2 JP 7562558 B2 JP7562558 B2 JP 7562558B2 JP 2021560095 A JP2021560095 A JP 2021560095A JP 2021560095 A JP2021560095 A JP 2021560095A JP 7562558 B2 JP7562558 B2 JP 7562558B2
- Authority
- JP
- Japan
- Prior art keywords
- plasmid
- rep
- gene
- helper
- cap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013612 plasmid Substances 0.000 title claims description 1247
- 108090000623 proteins and genes Proteins 0.000 claims description 451
- 239000013598 vector Substances 0.000 claims description 440
- 239000002773 nucleotide Substances 0.000 claims description 319
- 125000003729 nucleotide group Chemical group 0.000 claims description 317
- 239000002245 particle Substances 0.000 claims description 231
- 101150044789 Cap gene Proteins 0.000 claims description 228
- 102000004169 proteins and genes Human genes 0.000 claims description 225
- 238000004519 manufacturing process Methods 0.000 claims description 149
- 238000000034 method Methods 0.000 claims description 134
- 101150066583 rep gene Proteins 0.000 claims description 131
- 230000014509 gene expression Effects 0.000 claims description 121
- 241000700605 Viruses Species 0.000 claims description 93
- 108700019146 Transgenes Proteins 0.000 claims description 76
- 150000007523 nucleic acids Chemical class 0.000 claims description 72
- 238000002360 preparation method Methods 0.000 claims description 71
- 241000701161 unidentified adenovirus Species 0.000 claims description 62
- 238000010367 cloning Methods 0.000 claims description 42
- 108091034131 VA RNA Proteins 0.000 claims description 35
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 101150066038 E4 gene Proteins 0.000 claims description 25
- 241001135569 Human adenovirus 5 Species 0.000 claims description 25
- 238000012258 culturing Methods 0.000 claims description 25
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 23
- 108020004705 Codon Proteins 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 230000014621 translational initiation Effects 0.000 claims description 10
- 108020005350 Initiator Codon Proteins 0.000 claims description 9
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 claims description 7
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 claims description 6
- 241000701109 Human adenovirus 2 Species 0.000 claims description 4
- 101150028074 2 gene Proteins 0.000 claims description 3
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 claims description 2
- 102200157658 rs1555229948 Human genes 0.000 claims 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 261
- 241000702421 Dependoparvovirus Species 0.000 description 257
- 210000004027 cell Anatomy 0.000 description 253
- 238000003753 real-time PCR Methods 0.000 description 125
- 108020004414 DNA Proteins 0.000 description 115
- 239000000523 sample Substances 0.000 description 84
- 238000012360 testing method Methods 0.000 description 83
- 239000000047 product Substances 0.000 description 80
- 239000012634 fragment Substances 0.000 description 60
- 108010054218 Factor VIII Proteins 0.000 description 56
- 102000001690 Factor VIII Human genes 0.000 description 56
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 54
- 102100022641 Coagulation factor IX Human genes 0.000 description 54
- 108010076282 Factor IX Proteins 0.000 description 54
- 108010017544 Glucosylceramidase Proteins 0.000 description 54
- 102000004547 Glucosylceramidase Human genes 0.000 description 54
- 210000000234 capsid Anatomy 0.000 description 48
- 108010030291 alpha-Galactosidase Proteins 0.000 description 45
- 102000005840 alpha-Galactosidase Human genes 0.000 description 45
- 229960004222 factor ix Drugs 0.000 description 41
- 229960000301 factor viii Drugs 0.000 description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 34
- 238000003556 assay Methods 0.000 description 32
- 239000013607 AAV vector Substances 0.000 description 30
- 230000003362 replicative effect Effects 0.000 description 30
- 238000001890 transfection Methods 0.000 description 30
- 239000013592 cell lysate Substances 0.000 description 27
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 26
- 102000016911 Deoxyribonucleases Human genes 0.000 description 25
- 108010053770 Deoxyribonucleases Proteins 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000004806 packaging method and process Methods 0.000 description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 20
- 239000012091 fetal bovine serum Substances 0.000 description 20
- 230000006801 homologous recombination Effects 0.000 description 20
- 238000002744 homologous recombination Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 230000003321 amplification Effects 0.000 description 19
- 238000010790 dilution Methods 0.000 description 19
- 239000012895 dilution Substances 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 239000000499 gel Substances 0.000 description 19
- 238000003199 nucleic acid amplification method Methods 0.000 description 19
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 18
- 101710081079 Minor spike protein H Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 16
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 16
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 16
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 16
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 16
- 238000001415 gene therapy Methods 0.000 description 16
- 239000006166 lysate Substances 0.000 description 16
- 239000013608 rAAV vector Substances 0.000 description 16
- 201000001718 Roberts syndrome Diseases 0.000 description 15
- 208000012474 Roberts-SC phocomelia syndrome Diseases 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 101710132601 Capsid protein Proteins 0.000 description 14
- 101710197658 Capsid protein VP1 Proteins 0.000 description 14
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 14
- 101710108545 Viral protein 1 Proteins 0.000 description 14
- 230000006798 recombination Effects 0.000 description 14
- 238000005215 recombination Methods 0.000 description 14
- 230000010076 replication Effects 0.000 description 14
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 238000002105 Southern blotting Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 11
- 108091093088 Amplicon Proteins 0.000 description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 10
- 229920002873 Polyethylenimine Polymers 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 229920001993 poloxamer 188 Polymers 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000012131 assay buffer Substances 0.000 description 8
- 238000003306 harvesting Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 235000011089 carbon dioxide Nutrition 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000012096 transfection reagent Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 238000004115 adherent culture Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000000138 intercalating agent Substances 0.000 description 5
- 238000011880 melting curve analysis Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011535 reaction buffer Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 101100269369 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AGE1 gene Proteins 0.000 description 4
- 206010042566 Superinfection Diseases 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 210000000692 cap cell Anatomy 0.000 description 4
- 238000000432 density-gradient centrifugation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- -1 α-galactosyl Chemical group 0.000 description 4
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 3
- 101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 3
- 101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 3
- 101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000005001 rutherford backscattering spectroscopy Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108091008023 transcriptional regulators Proteins 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102100033391 ATP-dependent RNA helicase DDX3X Human genes 0.000 description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 241001244729 Apalis Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000870662 Homo sapiens ATP-dependent RNA helicase DDX3X Proteins 0.000 description 2
- 101100506223 Homo sapiens HAP1 gene Proteins 0.000 description 2
- 101000838883 Homo sapiens Hippocalcin-like protein 1 Proteins 0.000 description 2
- 102100039384 Huntingtin-associated protein 1 Human genes 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101100017567 Mycoplasma gallisepticum (strain R(low / passage 15 / clone 2)) hlp1 gene Proteins 0.000 description 2
- 108700005081 Overlapping Genes Proteins 0.000 description 2
- 108020004688 Small Nuclear RNA Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 101150017816 40 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 102100033416 60S acidic ribosomal protein P1 Human genes 0.000 description 1
- 101150102327 68 gene Proteins 0.000 description 1
- 101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 description 1
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 1
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 1
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 1
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 1
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 1
- YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 description 1
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 1
- 101710199711 Early E1A protein Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 1
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 1
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 1
- 101000712357 Homo sapiens 60S acidic ribosomal protein P1 Proteins 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 1
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 1
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 1
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 1
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 1
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 1
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 1
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 1
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 1
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 1
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 1
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 1
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 1
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 1
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000027832 depurination Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000013016 formulated drug substance Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1905263.8 | 2019-04-12 | ||
| EP19169121.1 | 2019-04-12 | ||
| GBGB1905263.8A GB201905263D0 (en) | 2019-04-12 | 2019-04-12 | Plasmid system |
| EP19169121.1A EP3722434B1 (en) | 2019-04-12 | 2019-04-12 | Plasmid system |
| PCT/GB2020/050947 WO2020208379A1 (en) | 2019-04-12 | 2020-04-14 | Plasmid system |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022530192A JP2022530192A (ja) | 2022-06-28 |
| JPWO2020208379A5 JPWO2020208379A5 (https=) | 2023-04-17 |
| JP2022530192A5 JP2022530192A5 (https=) | 2023-04-17 |
| JP7562558B2 true JP7562558B2 (ja) | 2024-10-07 |
Family
ID=70295566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560095A Active JP7562558B2 (ja) | 2019-04-12 | 2020-04-14 | プラスミドシステム |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220162642A1 (https=) |
| EP (1) | EP3953482A1 (https=) |
| JP (1) | JP7562558B2 (https=) |
| KR (1) | KR20220019669A (https=) |
| CN (1) | CN113891942A (https=) |
| AU (1) | AU2020272557A1 (https=) |
| BR (1) | BR112021020401A2 (https=) |
| CA (1) | CA3136545A1 (https=) |
| IL (2) | IL296544A (https=) |
| SG (1) | SG11202111149VA (https=) |
| WO (1) | WO2020208379A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| EP3722434B1 (en) | 2019-04-12 | 2022-07-27 | Freeline Therapeutics Limited | Plasmid system |
| EP4051704A2 (en) | 2019-11-01 | 2022-09-07 | Freeline Therapeutics Limited | Factor viii construct |
| JP2024504365A (ja) * | 2021-01-22 | 2024-01-31 | バイオジェン・エムエイ・インコーポレイテッド | 組換えウイルスベクター力価を増加させる微小管不安定化剤添加剤 |
| AU2022227005B2 (en) * | 2021-02-26 | 2025-09-11 | Logicbio Therapeutics, Inc. | Manufacturing and use of recombinant aav vectors |
| EP4410971A4 (en) * | 2021-09-30 | 2025-06-04 | FUJIFILM Corporation | METHOD FOR PRODUCING AN ADENO-ASSOCIATED VIRUS, CELLS AND EXPRESSION VECTOR |
| GB202214328D0 (en) | 2022-09-29 | 2022-11-16 | Freeline Therapeutics Ltd | Method |
| WO2024160232A1 (zh) * | 2023-02-01 | 2024-08-08 | 纽福斯(苏州)生物科技有限公司 | 质粒包装系统及其应用 |
| CN118633572A (zh) * | 2023-03-06 | 2024-09-13 | 北京锦篮基因科技有限公司 | 神经元核内包涵体病小鼠模型构建方法及应用 |
| WO2024223931A1 (en) * | 2023-04-28 | 2024-10-31 | AstraZeneca Ireland Limited | Manufacturing and use of recombinant self-complementary aav vectors |
| TW202525832A (zh) | 2023-08-31 | 2025-07-01 | 美商戴諾治療公司 | 衣殼多肽及其使用方法(二) |
| WO2025083617A1 (en) * | 2023-10-18 | 2025-04-24 | Nanocell Therapeutics Holdings B.V. | Methods and compositions for nucleic construct delivery |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| TW202548023A (zh) | 2024-03-14 | 2025-12-16 | 美商雅菲納治療公司 | 用於生產重組腺相關病毒的質體系統 |
| EP4628576A1 (en) | 2024-04-07 | 2025-10-08 | Ascend Advanced Therapies GmbH | Microrna molecules for use in methods for improving recombinant aav production |
| WO2025238067A1 (en) | 2024-05-15 | 2025-11-20 | Ascend Advanced Therapies Gmbh | Novel vector system for aav production |
| WO2026064444A1 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064428A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004508041A (ja) | 2000-09-08 | 2004-03-18 | メディジーン・アクチェンゲゼルシャフト | 組換え型アデノ随伴ウイルス（ｒＡＡＶ）をパッケージングする親細胞、それらの生成方法、およびその使用 |
| JP2004534543A (ja) | 2001-07-13 | 2004-11-18 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | シュードタイプ化アデノ関連ウイルスおよびその使用 |
| US20050080027A1 (en) | 2001-11-30 | 2005-04-14 | Markus Horer | Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2330826B1 (es) * | 2008-06-04 | 2010-07-26 | Proyecto De Biomedicina Cima, S.L. | Sistema para empaquetamiento de adenovirus de alta capacidad. |
| PL2403867T3 (pl) * | 2009-03-04 | 2019-12-31 | Deutsches Krebsforschungszentrum | Białko aktywujące składanie (aap) i jego zastosowanie do wytwarzania cząstek parwowirusa zasadniczo składających się z vp3 |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| JP6348064B2 (ja) | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| US10385320B2 (en) | 2015-12-02 | 2019-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| CN108048483B (zh) * | 2018-01-30 | 2021-02-02 | 中国疾病预防控制中心病毒病预防控制所 | 复制型重组腺病毒HAdV-5载体系统及其应用 |
-
2020
- 2020-04-14 AU AU2020272557A patent/AU2020272557A1/en active Pending
- 2020-04-14 JP JP2021560095A patent/JP7562558B2/ja active Active
- 2020-04-14 CN CN202080039790.8A patent/CN113891942A/zh active Pending
- 2020-04-14 EP EP20720111.2A patent/EP3953482A1/en active Pending
- 2020-04-14 WO PCT/GB2020/050947 patent/WO2020208379A1/en not_active Ceased
- 2020-04-14 CA CA3136545A patent/CA3136545A1/en active Pending
- 2020-04-14 US US17/602,941 patent/US20220162642A1/en not_active Abandoned
- 2020-04-14 KR KR1020217037076A patent/KR20220019669A/ko active Pending
- 2020-04-14 BR BR112021020401A patent/BR112021020401A2/pt unknown
- 2020-04-14 IL IL296544A patent/IL296544A/en unknown
- 2020-04-14 SG SG11202111149VA patent/SG11202111149VA/en unknown
-
2021
- 2021-10-07 IL IL287100A patent/IL287100A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004508041A (ja) | 2000-09-08 | 2004-03-18 | メディジーン・アクチェンゲゼルシャフト | 組換え型アデノ随伴ウイルス（ｒＡＡＶ）をパッケージングする親細胞、それらの生成方法、およびその使用 |
| JP2004534543A (ja) | 2001-07-13 | 2004-11-18 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | シュードタイプ化アデノ関連ウイルスおよびその使用 |
| US20050080027A1 (en) | 2001-11-30 | 2005-04-14 | Markus Horer | Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| Jpn J Cancer Res，1999年，vol. 90, no. 4，pp. 476-483 |
| Mol Ther，2003年，vol. 7, no. 6，pp. 839-850 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL296544A (en) | 2022-11-01 |
| KR20220019669A (ko) | 2022-02-17 |
| US20220162642A1 (en) | 2022-05-26 |
| JP2022530192A (ja) | 2022-06-28 |
| BR112021020401A2 (pt) | 2021-12-07 |
| EP3953482A1 (en) | 2022-02-16 |
| IL287100A (en) | 2021-12-01 |
| CN113891942A (zh) | 2022-01-04 |
| SG11202111149VA (en) | 2021-11-29 |
| CA3136545A1 (en) | 2020-10-15 |
| WO2020208379A1 (en) | 2020-10-15 |
| AU2020272557A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7562558B2 (ja) | プラスミドシステム | |
| EP3722434B1 (en) | Plasmid system | |
| US20230323387A1 (en) | Plasmid system | |
| US8409842B2 (en) | Recombinant adeno-associated virus production | |
| JP2001514845A (ja) | 組換えａａｖベクターの高力価ヘルパーなし調製物を生成するための方法 | |
| US20230076955A1 (en) | DNA Amplification Method | |
| WO2024211780A1 (en) | Compositions and methods for recombinant aav production | |
| TW202116794A (zh) | 用於生物製造之合成遺傳因子 | |
| US20250263746A1 (en) | Method for producing recombinant aav particles | |
| JP7834758B2 (ja) | 低レベルのｖａ－ｒｎａを有する産生細胞 | |
| US20260117255A1 (en) | Plasmid system | |
| EP4628576A1 (en) | Microrna molecules for use in methods for improving recombinant aav production | |
| WO2025238067A1 (en) | Novel vector system for aav production | |
| JP2026511015A (ja) | 組換えａａｖ粒子調製物の生成のための方法 | |
| WO2026068629A1 (en) | Methods and constructs for raav production | |
| WO2025168663A1 (en) | Method for producing recombinant adeno-associated viral particles | |
| WO2025038011A1 (en) | Modified sequence of adenovirus e2a gene for producing vectors based on adeno-associated viruses (aav) (variants) | |
| HK40061787A (en) | Dna amplification method | |
| CN118974274A (zh) | 用于确定aav基因组的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211214 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20211214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230407 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230407 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230901 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230901 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240628 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240917 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240925 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7562558 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |